ABSTRACT NUMBER: ESOC2026A2481 BEYOND INFARCT SIZE: THE ADDED PROGNOSTIC VALUE OF ADC-DERIVED RADIOLOGICAL LESION SEVERITY AFTER ACUTE ISCHEMIC STROKE Authors: Fabiano Cavalcante, Jonelle Marasigan, Manon Kappelhof, Kilian Treurniet, Wiktor Olszewski, Bart Emmer, Henk Marquering, Yvo Roos, Charles Majoie Published: 2026 ABSTRACT AbstractBackground and aimsWe investigated whether radiological lesion severity, quantified by voxel-level intensity on apparent diffusion coefficient (ADC) maps, provides prognostic information beyond total lesion volume.MethodsWe included patients from the MR CLEAN-NO IV randomized trial with available follow-up MRI 12–120 hours after randomization. Ischemic lesions were manually segmented. Radiological severity was characterized by (1) intensity-weighted lesion volume, inversely weighting voxel volume by ADC intensity; (2) volume of voxels with ADC <470; and (3) mean ADC intensity of the lesion. The primary outcome was the 90-day modified Rankin Scale (mRS). Associations were assessed using ordinal regression adjusted for prognostic covariates. Model discrimination was evaluated using optimism-corrected C-statistics.ResultsAmong 539 participants, 127 had follow-up MRI (median 26 hours; IQR 22–38). Median lesion volume was 8 mL (IQR 3–32), and median volume with ADC<470 was 2 mL (IQR 1–12). The median intensity-weighted lesion volume was 2 mL (IQR 0–6). Lesion volume was associated with outcome (aOR per 10 mL:1.10; 95% CI=1.01–1.21). Mean lesion intensity was also associated with functional outcomes (aOR 0.84; 95%CI=0.77 –0.91) after adjusting for total lesion volume, randomization to MRI time, and predefined prognostic factors. The predictive performance of models considering only the total lesion volume was modest (C-index=0.69, 95%CI=0.62-0.76) and was not significantly improved with inclusion of average lesion intensity (C-index=0.72, 95%CI=0.65-0.79) or the intensity weighted lesion volume (C-index=0.71, 95%CI=0.64-0.77).ConclusionsADC-derived radiological lesion severity captures biologically relevant information beyond infarct size but provided only marginal gains in outcome prediction.Conflict of interestDr Majoie reports grants from European Commission to other; grants from Health Evaluation Netherlands to other; grants from Stryker Corporation to other; stock holdings in Nicolab; grants from Dutch Heart Foundation to other; and grants from Boehringer Ingelheim to other. Dr Roos reports stock holdings in Nicolab. The other authors report no conflicts. All other authors have nothing to disclose.